Reference intervals of bone turnover markers in healthy premenopausal women: Results from a cross-sectional European study

Bone

Volumn 50, Issue 5, 2012, Pages 1141-1147

  Eastell, Richard ^a   Garnero, Patrick ^b   Audebert, Christine ^c   Cahall, David L ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b INSERM   (France)

^c TIMONE HOSPITAL   (France)

^d SANOFI   (France)

Author keywords

Assays; Bone turnover markers; Osteoporosis; Premenopausal women; Reference intervals

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; PARATHYROID HORMONE; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOMATION; BLOOD SAMPLING; BONE TURNOVER; CAUCASIAN; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DENMARK; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MICROTITER PLATE ASSAY; NORMAL HUMAN; PREMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REFERENCE VALUE; URINALYSIS;

ADULT; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; BONE REMODELING; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; EUROPE; FEMALE; HEALTH; HUMANS; PARATHYROID HORMONE; PREMENOPAUSE; REFERENCE VALUES; VITAMIN D;

EID: 84859435881     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.02.003     Document Type: Article

References (21)

1. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994, 79:1693-1700.
2. Delmas P.D., Handy P., Garnero P., Dain M.P. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000, 26:553-560.
3. de Papp A.E., Bone H.G., Caulfield M.P., Kagan R., Buinewicz A., Chen E., et al. A cross sectional study of bone turnover markers in healthy premenopausal women. Bone 2007, 40:1222-1230.
4. Srivastava A.K., Vliet E.L., Lewiecki E.M., Maricic M., Abdelmalek A., Gluck O., et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005, 21:1015-1026.
5. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051-1056.
6. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000, 15:1526-1536.
7. Rogers A., Glover S.J., Eastell R. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 2009, 45:1044-1052.
8. Glover S.J., Gall M., Schoenborn-Kellenberger O., Wagener M., Garnero P., Boonen S., et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009, 24:389-397.
9. Glover S.J., Garnero P., Naylor K., Rogers A., Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008, 42:623-630.
10. Adami S., Bianchi G., Brandi M.L., Giannini S., Ortolani S., DiMunno O., et al. Determinants of bone turnover markers in healthy premenopausal women. Calif. Tissue Int. 2008, 82:341-347.
11. Claudon A., Vergnaud P., Valverde C., Mayr A., Klause U., Garnero P. New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 2008, 54:1554-1563.
12. Vasikaran S., Eastell R., Bruyère O., Foldes A.J., Garnero P., Griesmacher A., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420.
13. Lips P., Bouillon R., van Schoor N.M., Vanderschueren D., Verschueren S., Kuchuk N., et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) 2010, 73:277-285.
14. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
15. Bauer D.C., Garnero P., Harrison S.L., Cauley J.A., Eastell R., Ensrud K.E., et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res 2009, 24:2032-2038.
16. Seibel M.J., Woitge H.W., Farahmand I., Oberwittler H., Ziegler R. Automated and manual assays for urinary crosslinks of collagen: which assay to use?. Exp Clin Endocrinol Diabetes 1998, 106:143-148.
17. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate?. J Steroid Biochem Mol Biol 2004, 89-90:611-614.
18. Adami S., Bertoldo F., Braga V., Fracassi E., Gatti D., Gandolini G., et al. 25-hydroxy vitamin D levels in healthy premenopausal women: association with bone turnover markers and bone mineral density. Bone 2009, 45:423-426.
19. Garnero P., Munoz F., Sornay-Rendu E., Delmas P.D. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007, 40:716-722.
20. Delmas P.D., Munoz F., Black D.M., Cosman F., Boonen S., Watts N.B., et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009, 24:1544-1551.
21. Eastell R., Rogers A., Ni X., Krege J.H. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporos Int 2011, 22:1927-1934.